Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis

BACKGROUND: Several major randomized control studies have demonstrated that mepolizumab, an anti-IL-5 monoclonal antibody, is effective for patients with severe eosinophilic asthma who show exacerbation or require systemic corticosteroid maintenance therapy. However, the predictive factors of the re...

Descripción completa

Detalles Bibliográficos
Autores principales: Numata, Takanori, Nakayama, Katsutoshi, Utsumi, Hirofumi, Kobayashi, Kenji, Yanagisawa, Haruhiko, Hashimoto, Mitsuo, Minagawa, Shunsuke, Ishikawa, Takeo, Hara, Hiromichi, Araya, Jun, Kuwano, Kazuyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790020/
https://www.ncbi.nlm.nih.gov/pubmed/31606052
http://dx.doi.org/10.1186/s12890-019-0952-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790020/
https://www.ncbi.nlm.nih.gov/pubmed/31606052
http://dx.doi.org/10.1186/s12890-019-0952-1

Ejemplares similares